Plain-English translation of NCT06417892 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether adding a PD-1 antibody to a two-drug combination ( and albumin-paclitaxel) helps people with advanced stomach cancer live longer and feel better. You would be randomly assigned to receive either the two-drug combination alone or the two-drug combination plus the additional immune therapy drug, depending on which group you're placed in.
When stomach cancer comes back or spreads after an initial immune therapy treatment, doctors need new options to help patients. This trial is testing whether combining these specific medications — one that blocks blood vessel growth in tumors and one that attacks cancer cells — works better when paired with an additional immune-boosting drug.
You likely qualify if…
You likely don't qualify if…
You will visit the treatment center before starting therapy and then for follow-up visits as clinically needed — there is no fixed schedule, so your doctor will determine what works best for you. You'll be randomly assigned to one of two groups: one receiving the two-drug combination, and the other receiving the two-drug combination plus an additional immune therapy drug. Throughout the study, your doctor will monitor you for side effects and how well the treatment is working, and you'll continue to be followed by phone, messaging, or through your doctor every 3 months after treatment ends.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment target
~60 participants
Started
April 2024
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
LIN YANG, Doctor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.